Megan Lockwood, MD
Rheumatology · Washington, DCNPI 1932593027
Payments from drug & device makers
What this record shows
This record is dominated by grants: $21,030 of the $23,101 with a category attached, or 91.0%. Pfizer accounts for 91.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $21,030 and has fallen 99.7% since, to $71 in 2025.
Across 16 payments — averaging $1443.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$21K
- Biogen$2K
- Amgen$71
- Aurinia Pharma U.S., Inc.$55
Across 11 payments — averaging $169.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
What the payments were for
- Grants$21,03091%
- Travel & lodging$1,2155%
- Food & beverage$8564%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $21,030 |
| Biogen | 13 | $1,946 |
| Amgen | 1 | $71 |
| Aurinia Pharma U.S., Inc. | 1 | $55 |
How this compares
$23,101 in reported general payments places this provider in the 80th percentile of 41 rheumatology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 37 | $305,840 |
| HumiraAdalimumab | 21 | $135,098 |
| BenlystaBelimumab | 11 | $51,036 |
| Actemra ActpenTocilizumab | 12 | $45,845 |
| Teriparatide | 16 | $39,186 |
| TymlosAbaloparatide | 13 | $35,780 |
| RasuvoMethotrexate/Pf | 16 | $8,752 |
| Hydroxychloroquine Sulfate | 108 | $4,673 |
| Prednisone | 141 | $1,485 |
| MethotrexateMethotrexate Sodium | 44 | $1,232 |
| Diclofenac Sodium | 29 | $870 |
| Pilocarpine Hcl | 13 | $869 |
| Cyclobenzaprine Hcl | 21 | $334 |
| Celecoxib | 11 | $295 |
| Alendronate Sodium | 26 | $242 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Washington
- Stephen MitchellWashington$1.6M
- Andrea Leonard-SegalWashington$633K
- Gail KerrWashington$244K
- Virginia SteenWashington$168K
- Sharon DowellWashington$73K
- Christopher CollinsWashington$69K
- Saira BilalWashington$62K
- Mercedes QuinonesWashington$23K
- Tayseer HarounWashington$18K
- Ndelela MbuyiWashington$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.